Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04779645Phase 2Active Not Recruiting

Effects of GRA in Patients With Type 1

Role: collaborator

NCT06272695Phase 1Completed

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

Role: lead

NCT03117998Phase 2Completed

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Role: lead

NCT04545411Phase 1Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Role: collaborator

NCT03919617Phase 1Completed

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

Role: collaborator

NCT02455011Phase 1Completed

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT02715193Phase 1Completed

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Role: lead

All 7 trials loaded